Aravive Investor Presentation Deck

Batiraxcept May Unlock -$3B in Global Revenue Across PROC, Renal and Pancreatic Tumors, with PROC Representing a Near-term Growth Driver Potential for Large Total Accessible Market Across Multiple Tumor Types Marketing Estimates / Indication ■ PROC (bevacizumab naïve) PROC (bevacizumab experienced) 2L ccRCC PDAC Estimated Treatable Patients PROC • 4K bev naïve (USA) 5.5K bev naïve (EU4/UK) Prior bev patients is half of bev naïve patients in these 2 regions ccRCC • 9K (USA) • 9.5 K (EU4/UK) PDAC • 37.5K (USA) .46K (EU4/UK) 11

View entire presentation